Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Nature Medicine|April 2, 2026
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Nature Medicine|March 21, 2026
Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Interactive Cardiovascular and Thoracic Surgery|November 4, 2021
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysisPieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohortErik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Nature Medicine|April 2, 2026
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Nature Medicine|March 21, 2026
Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Interactive Cardiovascular and Thoracic Surgery|November 4, 2021
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysisPieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohortErik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Pageof 11